Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-02
2007-01-02
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S384000
Reexamination Certificate
active
11064397
ABSTRACT:
This invention provides estrogen receptor modulators of formula I, having the structurewhere R1, R2, R3, R4, R5, R6, R7and R8are as defined in the specification.
REFERENCES:
patent: 4418068 (1983-11-01), Jones
patent: 5998402 (1999-12-01), Miller et al.
Wellington et al., “Management of postmenopausal osteoporosis”, Dis Manage Health Outcomes, vol. 11 (10), pp. 673-692.
Strehlow et al., “Modulation of Antioxidant Enzyme Expression and Function by Estrogen”, Journal of the American heart association, vol. 93, pp. 170-177.
Shughrue et al., “Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury”, Neuroscience, vol. 116, pp. 851-861.
Choi et al., “Synthetic approaches towards naphthoquinone antibiotics, Iolium alkaloids, and benzo [d] naphthopyran antibiotics”, Univ. Microfilms Int., order No. DA9000085. From: Diss. Abstr. Int. B 1990, 50(8), 3473.
Mendelsohn, M. E. et al., “The Protective Effects of Estrogen on the Cardiovascular System,” New England Journal of Medicine 340: 1801-1811 (1999).
Epperson, C. N. et al., “Gonadal Steroids in the Treatment of Mood Disorders,” Psychosomatic Medicine 61: 676-697 (1999).
Crandall, C. J., “Estrogen Replacement Therapy and Colon Cancer: A Clinical Review,” Journal of Womens Health & Gender Based Medicine 8: 1155-1166 (1999).
Monk, D. et al., “Use of Estrogens for the Prevention and Treatment of Alzhimer's Disease,” Dementia & Geriatric Cognitive Disorders 11: 1-10 (2000).
Hurn, P. D. et al., “Estrogen as a Neuroprotectant in Stroke,” Journal of Cerebral Blood Flow & Metabolism 20: 631-652 (2000).
Calvin, M., “Oestrogens and Wound Healing,” Maturitas 34: 195-210 (2000).
Finking, G. et al., “Die Wirkungen von Östrogen im kardiovaskulären System,” Zeitschrift fur Kardiologie 89: 442-453 (2000) (English abstract included).
Brincat, M. P., “Hormone replacement therapy and the skin,” Maturitas 35: 107-117 (2000).
Al-Azzawi, F., “The menopause and its treatment in perspective,” Postgraduate Medical Journal 77: 292-304 (2001).
Moggs, J. G. et al., “Estrogen receptors: orchestrators of pleiotropic cellular responses,” EMBO Reports 2: 775-781 (2001).
Hall, J. M. et al., “The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling,” Journal of Biological Chemistry 276: 36869-36872 (2001).
McDonnell, D. P., Principles Of Molecular Regulation, Ch. 20, Humana Press, pp. 351-361(2000) Totowa, New Jersey.
McKenna, N. J. et al., “Nuclear Receptor Coregulators: Cellular and Molecular Biology,” Endocrine Reviews 20: 321-344 (1999).
Quaedackers, M. E. et al., “4-Hydroxytamoxifen Trans-Represses Nuclear Factor-κB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)α, and Not through ERβ,” Endocrinology 142: 1156-1166 (2001).
Bhat, R. A. et al., “A Novel Human Estrogen Receptor β: Identification and Functional Analysis of Additional N-terminal Amino Acids,” Journal of Steroid Biochemistry & Molecular Biology 67: 233-240 (1998).
Pelzer, T. et al., “Estrogen Effects in the Myocardium: Inhibition of NF- κB DNA Binding by Estrogen Receptor-α and -β,” Biochemical & Biophysical Research Communications 286: 1153-7 (2001).
Levin, E. R., “Genome and Hormones: Gender Differences in PhysiologyInvited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors,” Journal of Applied Physiology 91: 1860-1867 (2001).
Levin, E. R., “Cellular Functions of the Plasma Membrane Estorgen Receptor,” Trends in Endocrinology & Metabolism 10: 374-377 (1999).
Green, S. et al., “Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A,” Nature 320: 134-9 (1986).
Kuiper, G. et al., “Cloning of a novel estrogen receptor expressed in rat prostate and ovary,” Proceedings of the National Academy of Sciences of the United States of America 93: 5925-5930 (1996).
Couse, J. F. et al., “Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse,” Endocrinology 138: 4613-4621 (1997).
Kuiper, G. et al., “Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β,” Endocrinology 138: 863-870 (1997).
Sar, M. et al., “Differential Expression of Estrogen Receptor- β and Esrogen Receptor-β in the Rat Ovary,” Endocrinology 140: 963-971 (1999).
Fitzpatrick, S. L. et al., “Expression of Estrogen Receptor- β Protein in Rodent Ovary,” Endocrinology 140: 2581-2591 (1999).
Cowley, S. M. et al., “Estrogen Receptors α and β Form Heterodimers on DNA,” Journal of Biological Chemistry 272: 19858-19862 (1997).
McDonnell, D. P., “Selective Estrogen Receptor Modulators (SERMs): A First Step in the Development of Perfect Hormone Replacement Therapy Regimen,” Journal of the Society for Gynecologic Investigation 7: S10-S15 (2000).
Goldstein, S. R. et al., “A Pharmacological review of selective oestrogen receptor modulators,” Human Reproduction Update 6: 212-224 (2000).
Pike, A. C. W. et al., “Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist,” Embo 18: 4608-4618 (1999).
Shiau, A. K. et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen,” Cell 95: 927-937 (Dec. 23, 1998).
Paige, et al., “Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β,” Proceedings of the National Academy of Sciences of the United States of America 96: 3999-4004 (1999).
Meyers, Marvin J, et al., “Estrogen Receptor Subtype-Selective Ligands: Asymmetric Synthesis and Biological Evaluation of cis- and trans-5,11-Dialkyl-5,6,11,12-tetrahydrochrysenes,”J. Med. Chem.(1999), 42(13), 2456-2468.
Black, L. J. et al., “Uterine Bioassay of Tamoxifen, Trioxifene and a New Estrogen Antagonist (LY117018) in Rats and Mice,” Life Sciences, 26, 1453 (1980).
Yagi K., “Short Communications—A Simple Fluorometric Assay for Lipoperoxide in Blood Plasma,” Biochem Med 15:212-216 (1976).
Peele, D. B. et al., “Effects of Selection Delays on Radial Maze Performance: Acquisition and Effects of Scopolamine,” Pharmacology, Biochemistry, and Behavior, 29:143-150, (1988).
Monyer, H. et al., “Glucose deprivation neuronal injury in cortical culture,” 1989, Brain Research 483:347-354.
Wroblewski, F. et al., “Lactic Dehydrogenase Activity in Blood,” 1955, Proc. Soc. Exp. Biol. Med. 90:210-213.
Murray, W.V. et al., “The Remarkably Facile Synthesis of 12-Methoxybenzo[d]-naphtho[2,3-b]pyran-5-one from Homophthalic Anhydride,”J Chem Research(S), 1991, 10, 279.
Knabe, J. et al., “Zur Konstitution eines Kondensationsproduktes aus Homophthalsäurehalbesterchlorid. 2. Mitt.: Synthese von 5-Hydroxy-3,4; 7,8-dibenzocumarin,”Archiv Der Pharmazie, 1964, 297(9), 550-553.
Belgaonkar, V.H. et al., “Isocoumarins: Part XIV—Synthesis of 3-Benzylisocoumarins & 3-Benzyl-1(2H)-isoquinolones,”Indian Journal of Chemistry, Apr. 1975, 13, 336-338.
Shcherbakova, I.V. et al., “Formation of 2-naphthols . . . ,”Zhurnal Organicheskoi Khimii, 1989, 25(1), 164-171.
Edsall, Jr. Richard James
Mewshaw Richard Eric
Rahmani Niloofar
Seaman Margaret D.
Woodcock & Washburn LLP
Wyeth
LandOfFree
Dibenzo chromene derivatives and their use as ERβ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dibenzo chromene derivatives and their use as ERβ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dibenzo chromene derivatives and their use as ERβ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3733220